DanDrit Biotech A/S entered into merger agreement to acquire DKTI A/S (CPSE: DKTI) from Small Cap Danmark A/S (CPSE: SCD) in a reverse merger transaction on December 22, 2011. The merger is subject to DKTI's satisfactory review of due diligence investigation of Dandrit and Dandrit's satisfactory review of due diligence investigation of DKTI, approval of Dandrit and DKTI shareholders, approval FSA and NASDAQ OMX Copenhagen A / S and external advisors to DKTI gives a satisfactory confirmation of Nordic Biotech Investors assess Dandrits value. The transaction is expected to be completed by March 2012.

DanDrit Biotech A/S cancelled the acquisition of DKTI A/S (CPSE: DKTI) from Small Cap Danmark A/S (CPSE: SCD) in a reverse merger transaction on May 29, 2013.